In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHF (AIDS Healthcare Foundation) engages in Mexican HIV/STI services investment partnership:

This article was originally published in Clinica

Executive Summary

The AIDS Healthcare Foundation, a US not-for-profit HIV/AIDS care, research and prevention organisation, yesterday opened its third centre for sexually-transmitted infections (STIs) and HIV in Mexico. In partnership with the government, which has unveiled plans to build a network of 51 so-called CAPASITS centres (see related story), the Cancun (Quintana Roo state) clinic joins those currently being run by AHF in Tijuana (since October 2005) and Puerto Vallarta (since November 2006). The AHF is planning to open a fourth clinic later this year in the city of La Paz (Baja California Sur state). The Los Angeles-based group also operates a similar centre in Guatemala, in the city of Quetzaltenango.

You may also be interested in...



Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel